Evidence map›Paper›PMID 37228268›Full record

ArticleERJ open research2023

External validation and longitudinal application of the DO-GAP index to individualise survival prediction in idiopathic pulmonary fibrosis.

Abhimanyu Chandel, Christopher S King, Rosalinda V Ignacio, Jean Pastre, Oksana A Shlobin, Vikramjit Khangoora, Shambhu Aryal, Alan Nyquist, Anju Singhal, Kevin R Flaherty and 1 more

Open access · goldAbstract read
In one paragraph

Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Abhimanyu ChandelDepartment of Pulmonary and Critical Care, Walter Reed National Military Medical Center, Bethesda, MD, USA.ORCID https://orcid.org/0000-0003-4879-1983
Christopher S KingAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Rosalinda V IgnacioDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Jean PastreService de Pneumologie et Soins Intensifs, Hôpital Européen Georges Pompidou, APHP, Paris, France.
Oksana A ShlobinAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Vikramjit KhangooraAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Shambhu AryalAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Alan NyquistAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.ORCID https://orcid.org/0000-0002-2809-2416
Anju SinghalAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.
Kevin R FlahertyDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Steven D NathanAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.ORCID https://orcid.org/0000-0002-6270-1617
Inova Fairfax Hospital · USUniversity of Michigan · USAssistance Publique – Hôpitaux de Paris · FRWalter Reed National Military Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Distance-Oxygen-Gender-Age-Physiology (DO-GAP) index has been shown to improve prognostication in idiopathic pulmonary fibrosis (IPF) compared to the Gender-Age-Physiology (GAP) score. We sought to externally validate the DO-GAP index compared to the GAP index for baseline risk assessment in patients with IPF. Additionally, we evaluated the utility of serial change in the DO-GAP index in predicting survival. Methods: We performed an analysis of patients with IPF from the Pulmonary Fibrosis Foundation-Patient Registry (PFF-PR). Discrimination and calibration of the two models were assessed to predict transplant-free survival and IPF-related mortality. Joint longitudinal time-to-event modelling was utilised to individualise survival prediction based on DO-GAP index trajectory. Results: There were 516 patients with IPF from the PFF-PR with available demographics, pulmonary function tests, 6-min walk test data and outcomes included in this analysis. The DO-GAP index (C-statistic: 0.73) demonstrated improved discrimination in discerning transplant-free survival compared to the GAP index (C-statistic: 0.67). DO-GAP index calibration was adequate, and the model retained predictive accuracy to identify IPF-related mortality (C-statistic: 0.74). The DO-GAP index was similarly accurate in the subset of patients taking antifibrotic medications. Serial change in the DO-GAP index improved model discrimination (cross-validated area under the curve: 0.83) enabling the personalised prediction of disease trajectory in individual patients. Conclusion: The DO-GAP index is a simple, validated, multidimensional score that accurately predicts transplant-free survival in patients with IPF and can be adapted longitudinally in individual patients. The DO-GAP may also find use in studies of IPF to risk stratify patients and possibly as a clinical trial end-point.

Identifiers

PMID37228268
PMCPMC10204731
OpenAlexW4378348414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.